Archive


Warning: getimagesize(/home/isofolme/public_html/wp-content/uploadshttps://www.pharmasalmanac.com/hubfs/2236109/PA_logo_Hoz_2019.svg): failed to open stream: No such file or directory in /home/isofolme/public_html/wp-content/themes/joyn/includes/plugins/aq_resizer-1x.php on line 80

  • Pareto Securities´ Healthcare Conference 2021

    Isofol attended Pareto Securities´ Healthcare Conference on September 1, 2021. If you missed the live broadcast, you´re able watch it…

    by

  • Interview with Isofol´s CEO made by Pareto Securities

    See the interview with our CEO, Ulf Jungnelius, that was made by Pareto Securities, in connection to the announced rights…

    by

  • Abstract at the upcoming ASCO meeting in June 2021

    Isofol will present an abstract at the annual ASCO meeting between June 4- June 8. Together with scientists from Sahlgrenska…

    by

  • Interviewed made by Redeye

    Redeye has interviewed Ulf Jungnelius, CEO of Isofol, regarding the announcement that the AGENT study will be completed with 440…

    by

  • The abstract for AACR 2021 has been published

    The approved abstract for the congress American Association for Cancer Research (AACR) 2021 has been published on their website. The…

    by

  • Isofol announces that an abstract has been approved for AACR in April 2021

    Isofol announces that an abstract has been approved for presentation at the virtual American Association for Cancer Research (AACR) Congress…

    by

  • Isofol to present gene expression results from the completed Phase I/IIa ISO-CC-005 study today at ASCO-GI 2021 and updates of the timing of the interim analysis in the AGENT study

    GOTHENBURG, Sweden, January 15, 2021 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by

  • Isofol reaches 440 patients in global Phase III AGENT study

    GOTHENBURG, Sweden, December 9, 2020 - Isofol Medical AB (publ) (“Isofol”), (Nasdaq First North Premier Growth Market: ISOFOL) announces that…

    by

  • Isofol presents an abstract at ASCO GI in January 2021

    Isofol announces that an abstract, including arfolitixorin in the ISO-CC-005 study, has been accepted to be presented at ASCO GI…

    by

  • Arfolitixorin is presented as one of the most promising pipeline drugs in the new CRC report by Global Data

    Global Data recently published an outlook for the CRC market between 2018 and 2028 for the 8 major markets (8MM),…

    by

  • Empowered patient podcast

    Our CEO, Dr. Ulf Jungnelius, was featured on Karen Jagoda’s empowered patient podcast to discuss colorectal cancer and how our…

    by

  • Presentation and poster at ASCO Gastrointestinal Cancers Symposium

    Isofol is attending the event and will present details in the ongoing global Phase 3 AGENT clinical study (ISO-CC-007) Presentation…

    by

  • Pharma’s Almanac – Round table

    Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round table” segment. He discussed the…

    by

  • Published abstract at ESMO

    Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic…

    by

  • Poadcast – “The Cancer Gene”

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…

    by
  • aside

    Isofol has participated in the Empowered Patient Podcast

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO…

    by
    0